Omeros Corp. (OMER), a clinical-stage biopharmaceutical company, Monday reported fourth-quarter net loss of $7.73 million or $0.30 per share, narrower than last years' loss of $10.20 million or $0.46 per share last year.
Revenues for the quarter were $1.58 million compared to $1.14 million last year.
Research and development expenses increased to $9.35 million from $8.90 million last year. General and administrative costs increased to $3.72 million from $2.10 million last year.
For comments and feedback: editorial@rttnews.com